First Nebraska Trust Co Buys Shares of 15,650 Stryker Corporation $SYK

Key Points

• First Nebraska Trust Co. acquired 15,650 Stryker shares during the second quarter, valued at approximately $4.93 million. Institutional investors collectively own about 77.1% of the company.
• Stryker’s latest quarter exceeded expectations, with EPS of $3.69 and revenue of $6.59 billion, up 9.4% year over year. The company maintained fiscal 2026 earnings guidance of $14.95–$15.10 per share and declared a quarterly dividend of $0.88.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $386.28, although several firms recently lowered targets. Insider selling—including more than 665,000 shares sold over the past three months—may weigh on investor sentiment.

First Nebraska Trust Co bought a new stake in shares of Stryker Corporation (NYSE:SYK - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 15,650 shares of the medical technology company's stock, valued at approximately $4,927,000.

A number of other hedge funds also recently bought and sold shares of SYK. VanderPol Investments L.L.C. increased its holdings in Stryker by 1.4% during the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company's stock valued at $732,000 after buying an additional 28 shares during the last quarter. KCM Investment Advisors LLC raised its holdings in Stryker by 1.5% in the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company's stock worth $653,000 after purchasing an additional 28 shares during the period. Rossby Financial LCC lifted its position in Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company's stock valued at $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC increased its position in Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company's stock worth $403,000 after buying an additional 29 shares in the last quarter. Finally, ICW Investment Advisors LLC lifted its position in shares of Stryker by 0.6% during the 4th quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company's stock valued at $1,791,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada reduced their price objective on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research note on Friday, July 31st. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Truist Financial upped their price target on Stryker from $330.00 to $340.00 and gave the stock a "hold" rating in a research note on Friday, July 31st. Leerink Partners cut their target price on shares of Stryker from $410.00 to $407.00 and set an "outperform" rating for the company in a research note on Friday, June 5th. Finally, Citizens Jmp reduced their price target on shares of Stryker from $440.00 to $400.00 and set a "market outperform" rating on the stock in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $386.28.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Stock Performance

NYSE SYK opened at $329.86 on Friday. The business's 50 day moving average price is $326.99 and its 200-day moving average price is $332.64. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The company has a market cap of $126.52 billion, a P/E ratio of 34.18, a P/E/G ratio of 2.10 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm's quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts predict that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker's dividend payout ratio (DPR) is currently 36.48%.

Insiders Place Their Bets

In related news, VP Robert S. Fletcher sold 4,544 shares of the company's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at $2,088,423. The trade was a 11.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 665,370 shares of company stock valued at $216,238,501. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source